finance.yahoo.com ·
international flavors fragrances q1 earnings 000440264
Topic context
This topic has been covered 288663 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedIFF's earnings beat is company-specific, driven by volume growth in Health & Biosciences. No direct commodity or supply chain shock; the reaffirmed guidance suggests stable input costs. The impact is single-company/supply-chain-specific, with no broader sector disruption.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- IFF Q1 2026 revenue $2.7B, +3% comparable currency-neutral
- Adjusted operating EBITDA $568M, +8%
- Free cash flow $92M
- Health & Biosciences segment sales $595M, +5% driven by volume
- Full-year guidance: sales $10.5B-$10.8B, EBITDA $2.05B-$2.15B
Stable guidance suggests no mid-term margin pressure for flavors and fragrances.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- CONSUMER_STAPLESmid
- GLOBAL_INDUSTRIALSmid